Autres langues Sernova Toronto S.E.

Actions

SVA

CA81732W1041

Equipement, fournitures et distribution médicale

Temps Différé Toronto S.E. Autres places de cotation 15:59:26 29/06/2026			Varia. 5j.	Varia. 1 janv.
0,1300 ^CAD	-7,14%		-6,67%	+7,69%

17/06	Sernova : désignation de médicament orphelin pour sa transplantation d'îlots autologues dans la prévention du diabète de type 3c	MT
11/06	Sernova Biotherapeutics Inc publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 avril 2026	CI

Autres langues

17/06	Sernova's Autologous Islet Transplantation Gets Orphan Drug Designation For Type 3c Diabetes Prevention
17/06	Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy
11/06	Sernova Biotherapeutics Inc Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026
23/04	Sernova Biotherapeutics Announces Closing of Recently Approved Financings
23/04	Sernova Biotherapeutics Inc announced that it has received CAD 7.564399 million in funding
09/04	Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders
24/03	Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing
16/03	Sernova Biotherapeutics : 2026 Q1 MD&A
16/03	Sernova Biotherapeutics : 2026 Q1 Financial Statements
13/03	Sernova Biotherapeutics Inc Reports Earnings Results for the First Quarter Ended January 31, 2026
09/03	Sernova Biotherapeutics : Appointment of Proxyholder (SVA 2026 Proxy)
09/03	Sernova Biotherapeutics : Voting Instruction Form (VIF) (SVA 2026 VIF)
09/03	Sernova Biotherapeutics : Combined Circular with Schedules (SVA 2026 Combined Circular w Schedules)
04/03	Sernova Biotherapeutics Inc announced that it expects to receive CAD 7.1 million in funding
04/03	Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval
20/02	Sernova Biotherapeutics Announces Warrant Amendments
12/01	Sernova Biotherapeutics : 2025 Annual Information Form
12/01	Sernova Biotherapeutics : 2025 Q4 MD&A
12/01	Sernova Biotherapeutics : 2025 Q4 Financial Statements
19/12	Sernova Biotherapeutics Inc Reports Earnings Results for the Full Year Ended October 31, 2025
19/12	Sernova Biotherapeutics Inc Auditor Raises 'Going Concern' Doubt
13/11	Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts
13/11	Sernova Biotherapeutics Inc announced that it expects to receive CAD 5 million in funding
01/10/25	Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang
23/09/25	Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors